High SOX2 levels predict better outcome in non-small cell lung carcinomas.
| Autor: | Vamsidhar Velcheti, Kurt Schalper, Xiaopan Yao, Huan Cheng, Mehmet Kocoglu, Kavita Dhodapkar, Yanhong Deng, Scott Gettinger, David L Rimm |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | PLoS ONE, Vol 8, Iss 4, p e61427 (2013) |
| Druh dokumentu: | article |
| ISSN: | 1932-6203 97506508 |
| DOI: | 10.1371/journal.pone.0061427 |
| Popis: | BACKGROUND: SOX2 is an embryonic developmental transcription factor, which is important in the development of the respiratory tract. SOX2 overexpression is associated with aggressive disease in several tumor types. However, SOX2 overexpression and gene amplification associates with favorable outcome in lung squamous cell carcinomas (SCC) and dissimilar results have been reported in lung adenocarcinomas (ADC). The aim of the present study was to evaluate SOX2 expression in NSCLC and determine the relationship with clinico-pathological variables and outcome. METHODS: SOX2 protein levels were measured in tissue microarrays (TMAs) containing FFPE samples from two independent lung cancer cohorts (n = 340 & 307) using automated quantitative immunofluorescence (QIF). Assay validation was performed using FFPE preparations of cell lines with known SOX2 expression. Associations of SOX2 levels with main clinico-pathological characteristics and with overall survival were studied using uni-and multivariate analysis. RESULTS: SOX2 levels were higher in patients with SCC than in ADC in both cohorts (p value |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|